Pfizer Finds Success With Chantix Clinical Study
A clinical study involving Pfizer, Inc.’s (NYSE:PFE) Chantix was a success, the company announced Tuesday. The study, which assessed the efficacy and safety of the drug, also known as varenicline, met its primary and secondary endpoints, according to Business Wire.
The study is the first involving varenicline to approach the goal of smoking-cessation by first reducing smoking prior to patients quitting outright. The trial addressed in particular smokers who were either unwilling or unable to quit smoking within four weeks, but had agreed to reduce the amount they smoked over a 12 week period with the goal of eventually quitting by the end of that period.
Smoking reduction prior to cessation is now a common approach to treatment, as many smokers find a fixed “quit date” intimidating, according to Stephen J. Romano, M.D., who works for Pfizer as Senior vice president and Head of the Medicines Development Group. Smokers in the Chantix trial were treated for both a 12-week reduction phase followed by a 12-week abstinence phase, for a total of 24 weeks of treatment. “This study was designed with this quitting approach in mind,” Romano continued.